Stocks · News reference

Fortress Biotech Q2 EPS $(0.08) Beats $(0.20) Estimate, Sales $18.718M Beat $18.300M Estimate

Aug 13, 2026, 8:28 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaJul 27, 2026, 12:03 PMBenzinga Newsdesk
Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad
Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in
Read original at benzinga
FBIO